Pipeline

EU301
Indication B-cell precursor ALL
Diffuse large B-cell lymphoma (DLBCL)
Target /Drug class HLA-DR expressing cancer cell / CAR-T Development Stage Non-clinical
Summary
  • MVR CAR-T can be used against HLA-DR positive cancer, as well as B cell malignancy.
  • The epitopes recognized by HLA-DR are not shed or internalized, enabling stable binding to human lymphoma cells.
  • MVR CAR-T can also be used in patients who relapse after CD19 CAR-T treatment.
  • Reduction of cytokine secretion due to selective killing of tumor cells.
in vivo Efficacy
Mode of Action